0001209191-22-000730.txt : 20220104
0001209191-22-000730.hdr.sgml : 20220104
20220104161957
ACCESSION NUMBER: 0001209191-22-000730
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220104
DATE AS OF CHANGE: 20220104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hansen Gwenn
CENTRAL INDEX KEY: 0001817160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 22506239
MAIL ADDRESS:
STREET 1: C/O NURIX THERAPEUTICS, INC.
STREET 2: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1130
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-03
0
0001549595
Nurix Therapeutics, Inc.
NRIX
0001817160
Hansen Gwenn
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Scientific Officer
Common Stock
2022-01-03
4
M
0
400
7.26
A
14597
D
Common Stock
2022-01-03
4
M
0
1428
9.57
A
16025
D
Common Stock
2022-01-03
4
S
0
1828
28.96
D
14197
D
Employee Stock Option (right to buy)
7.26
2022-01-03
4
M
0
400
0.00
D
2030-02-26
Common Stock
400
67466
D
Employee Stock Option (right to buy)
9.57
2022-01-03
4
M
0
1428
0.00
D
2030-05-27
Common Stock
1428
81905
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
/s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
2022-01-04